San Francisco, California – Natera, Inc. reported their Q3 2024 Earnings in a conference call held on November 12th, 2024 at 4:30 AM ET. The call included key company participants such as Mike Brophy, CFO; Steve Chapman, CEO; and Alexey Aleshin, GM Oncology and CMO. Among the conference call participants were Puneet Souda from Leerink Partners, Tejas Savant from Morgan Stanley, and Rachel Vatnsdal from JP Morgan.

During the call, Natera’s Chief Financial Officer, Michael Brophy, presented the financial results for the third quarter of 2024. CEO Steve Chapman and GM Oncology and CMO, Alexey Aleshin, also provided insights into the performance and strategic direction of the company. Despite the absence of Solomon Moshkevich, President of Clinical Diagnostics, due to other commitments, the team assured his presence in the upcoming quarter.

Natera’s conference call was streamed live via webcast and accompanied by a slide presentation available on their investor website. Brophy highlighted the company’s forward-looking statements, discussing future events, operational outlook, market strategies, and product developments. The team also emphasized the importance of partnerships, clinical studies, and expected outcomes for their various products.

Investors and analysts, including Douglas Schenkel from Wolfe Research and Matthew Sykes from Goldman Sachs, were keen on understanding Natera’s performance and future trajectory. The Q&A session following the management’s remarks provided further insights into the company’s financial projections and growth strategies. The call was recorded to ensure accurate documentation of the discussions held on November 12th, 2024.